Drug Index



Mechanism :

Piperazine phenothiazine antipsychotic which blocks dopamine, subtype 2 (D2), receptors in mesolimbocortical and nigrostriatal areas of the brain.

Indication :

• Schizophrenia

• Nausea/vomiting

• Off-label: Psychosis/agitation associated with dementia

Contraindications :

Hypersensitivity to perphenazine or any component of the formulation; severe CNS depression; subcortical brain damage with or without hypothalamic damage (known or suspected); bone marrow suppression; blood dyscrasias; liver damage.

Dosing :


≥12 years: 8 to 16 mg/day PO in divided doses.

Adverse Effect :

Bradycardia, ECG changes, hypertension, hypotension, orthostatic hypotension, Bizarre dream, catatonic-like state, cerebral edema, confusion (nocturnal), disruption of body temperature regulation, dizziness, drowsiness, extrapyramidal reaction, neuroleptic malignant syndrome (NMS), paradoxical excitation, Diaphoresis, pallor, skin discoloration (blue-grey), Amenorrhea, change in libido, galactorrhea, glycosuria, gynecomastia, hyperglycemia, hypoglycemia, menstrual disease, SIADH, Anorexia, constipation, diarrhea, faecal impaction, increased appetite, Blurred vision, corneal changes, epithelial keratopathy, Hypersensitivity reaction, Lupus-like syndrome.

Interaction :

Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents.
Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid.
Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride.
Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.
CYP2D6 Inhibitors: May decrease the metabolism of CYP2D6 Substrates.
Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.

03/06/2020 15:23:43 Perphenazine
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0